cholangiocarcinoma

Summary

Summary: A malignant tumor arising from the intrahepatic bile duct epithelium. It is composed of ducts lined by cuboidal or columnar cells that do not contain bile, with abundant stroma. (From Holland et al., Cancer Medicine, 3d ed, p1455; Stedman, 25th ed)

Top Publications

  1. pmc Risk factors for cholangiocarcinoma
    Gia L Tyson
    Section of Gastroenterology at the Michael E DeBakey Veterans Affairs Medical Center and Baylor College of Medicine, Houston, TX 77030, USA
    Hepatology 54:173-84. 2011
  2. ncbi Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance
    Andreas Karakatsanis
    Aretaieion Hospital, Surgical Department, School of Medicine, University of Athens, Greece
    Mol Carcinog 52:297-303. 2013
  3. ncbi Exome sequencing of liver fluke-associated cholangiocarcinoma
    Choon Kiat Ong
    National Cancer Centre Singapore Van Andel Research Institute Translational Research Laboratory, Division of Medical Sciences, Singapore
    Nat Genet 44:690-3. 2012
  4. ncbi Cholangiocarcinoma
    Shahid A Khan
    Liver Unit, Division of Medicine, St Mary s Hospital Campus, Faculty of Medicine, Imperial College London, London, UK
    Lancet 366:1303-14. 2005
  5. ncbi The epidemiology of cholangiocarcinoma
    Yasser Shaib
    Sections of Gastroenterology and Health Services Research, The Houston Veterans Affairs Medical Center and Baylor College of Medicine, Houston, Texas 77030, USA
    Semin Liver Dis 24:115-25. 2004
  6. pmc Opisthorchiasis and Opisthorchis-associated cholangiocarcinoma in Thailand and Laos
    Banchob Sripa
    Tropical Disease Research Laboratory, Department of Pathology, Khon Kaen University, Khon Kaen 40002, Thailand
    Acta Trop 120:S158-68. 2011
  7. pmc Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma
    Ting Lei Gu
    Cell Signaling Technology, Danvers, Massachusetts, United States of America
    PLoS ONE 6:e15640. 2011
  8. pmc CD133: a potential indicator for differentiation and prognosis of human cholangiocarcinoma
    Linni Fan
    State Key Laboratory of Cancer Biology and Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi an 710032, China
    BMC Cancer 11:320. 2011
  9. pmc MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint
    Alexandru V Olaru
    Division of Gastroenterology and Hepatology, Johns Hopkins Hospital, Baltimore, MD 21205, USA
    Hepatology 54:2089-98. 2011
  10. pmc E/N-cadherin switch mediates cancer progression via TGF-β-induced epithelial-to-mesenchymal transition in extrahepatic cholangiocarcinoma
    K Araki
    Department of General Surgical Science Surgery 1, Gunma University Graduate School of Medicine, 3 39 22 Showa machi, Maebashi, Gunma, Japan
    Br J Cancer 105:1885-93. 2011

Detail Information

Publications342 found, 100 shown here

  1. pmc Risk factors for cholangiocarcinoma
    Gia L Tyson
    Section of Gastroenterology at the Michael E DeBakey Veterans Affairs Medical Center and Baylor College of Medicine, Houston, TX 77030, USA
    Hepatology 54:173-84. 2011
    b>Cholangiocarcinoma (CC) is the second most common primary hepatic malignancy after hepatocellular cancer. CC accounts for approximately 10%-25% of all hepatobiliary malignancies...
  2. ncbi Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance
    Andreas Karakatsanis
    Aretaieion Hospital, Surgical Department, School of Medicine, University of Athens, Greece
    Mol Carcinog 52:297-303. 2013
    ..145, -146a, - 200c, -221, -222 and -223) in patients with hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), as well as to assess their prognostic significance...
  3. ncbi Exome sequencing of liver fluke-associated cholangiocarcinoma
    Choon Kiat Ong
    National Cancer Centre Singapore Van Andel Research Institute Translational Research Laboratory, Division of Medical Sciences, Singapore
    Nat Genet 44:690-3. 2012
    Opisthorchis viverrini-related cholangiocarcinoma (CCA), a fatal bile duct cancer, is a major public health concern in areas endemic for this parasite. We report here whole-exome sequencing of eight O...
  4. ncbi Cholangiocarcinoma
    Shahid A Khan
    Liver Unit, Division of Medicine, St Mary s Hospital Campus, Faculty of Medicine, Imperial College London, London, UK
    Lancet 366:1303-14. 2005
    b>Cholangiocarcinoma is a devastating malignancy that presents late, is notoriously difficult to diagnose, and is associated with a high mortality. The incidence of intrahepatic cholangiocarcinoma is increasing worldwide...
  5. ncbi The epidemiology of cholangiocarcinoma
    Yasser Shaib
    Sections of Gastroenterology and Health Services Research, The Houston Veterans Affairs Medical Center and Baylor College of Medicine, Houston, Texas 77030, USA
    Semin Liver Dis 24:115-25. 2004
    The incidence rates of cholangiocarcinoma (CC) vary greatly among different areas of the world, and this variation is related to distribution of risk factors...
  6. pmc Opisthorchiasis and Opisthorchis-associated cholangiocarcinoma in Thailand and Laos
    Banchob Sripa
    Tropical Disease Research Laboratory, Department of Pathology, Khon Kaen University, Khon Kaen 40002, Thailand
    Acta Trop 120:S158-68. 2011
    ..viverrini through these two regions. We also review the association of O. viverrini infection and cholangiocarcinoma, bile duct cancer, and highlight new findings on pathogenesis of liver fluke-induced cholangiocarcinogenesis...
  7. pmc Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma
    Ting Lei Gu
    Cell Signaling Technology, Danvers, Massachusetts, United States of America
    PLoS ONE 6:e15640. 2011
    b>Cholangiocarcinoma, also known as bile duct cancer, is the second most common primary hepatic carcinoma with a median survival of less than 2 years. The molecular mechanisms underlying the development of this disease are not clear...
  8. pmc CD133: a potential indicator for differentiation and prognosis of human cholangiocarcinoma
    Linni Fan
    State Key Laboratory of Cancer Biology and Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi an 710032, China
    BMC Cancer 11:320. 2011
    ..Nevertheless, the expression of CD133 in human cholangiocarcinoma (CC) is rare and our study is to detect the expression and explore the potential functions of CD133 in human ..
  9. pmc MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint
    Alexandru V Olaru
    Division of Gastroenterology and Hepatology, Johns Hopkins Hospital, Baltimore, MD 21205, USA
    Hepatology 54:2089-98. 2011
    ..pathways and mechanisms through which miR-494, one of the miR species found to be down-regulated in cholangiocarcinoma (CCA), participates in cancer homeostasis...
  10. pmc E/N-cadherin switch mediates cancer progression via TGF-β-induced epithelial-to-mesenchymal transition in extrahepatic cholangiocarcinoma
    K Araki
    Department of General Surgical Science Surgery 1, Gunma University Graduate School of Medicine, 3 39 22 Showa machi, Maebashi, Gunma, Japan
    Br J Cancer 105:1885-93. 2011
    ..This study aimed to investigate whether cadherin switch promotes cancer progression in cholangiocarcinoma (CC).
  11. ncbi Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma
    Regina V Tse
    Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 26:657-64. 2008
    To report outcomes of a phase I study of individualized stereotactic body radiotherapy treatment (SBRT) for unresectable hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC).
  12. ncbi Intratumoral IL-17⁺ cells and neutrophils show strong prognostic significance in intrahepatic cholangiocarcinoma
    Fang Ming Gu
    Liver Cancer Institute, Zhongshan Hospital and Shanghai Medical School, Fudan University, Shanghai, People s Republic of China
    Ann Surg Oncol 19:2506-14. 2012
    ..This study was designed to assess the clinical significance of tumor-infiltrating inflammatory cells in patients with intrahepatic cholangiocarcinoma (ICC).
  13. pmc Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma
    Vikram Deshpande
    Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, Massachusetts 02114, USA
    BMC Cancer 11:60. 2011
    ..The genetics of advanced biliary tract cancers (BTC), which encompass intra- and extra-hepatic cholangiocarcinomas as well as gallbladder carcinomas, are heterogeneous and remain to be fully defined...
  14. ncbi Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update
    Shahid A Khan
    Department of Hepatology and Gastroenterology Section, Imperial College London, London, UK
    Gut 61:1657-69. 2012
    The British Society of Gastroenterology guidelines on the management of cholangiocarcinoma were originally published in 2002...
  15. pmc Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document
    S A Khan
    Liver Unit, Department of Medicine A, Imperial College School of Medicine, St Mary s Hospital Campus, South Wharf Street, London W2 1PG, UK
    Gut 51:VI1-9. 2002
  16. pmc Liver fluke induces cholangiocarcinoma
    Banchob Sripa
    Department of Pathology, Khon Kaen University, Khon Kaen, Thailand
    PLoS Med 4:e201. 2007
  17. ncbi Epidemiology of cholangiocarcinoma: an update focusing on risk factors
    Hai Rim Shin
    International Agency for Research on Cancer, Lyon, France
    Cancer Sci 101:579-85. 2010
    b>Cholangiocarcinoma is relatively rare, but high incidence rates have been reported in Eastern Asia, especially in Thailand. The etiology of this cancer of the bile ducts appears to be mostly due to specific infectious agents...
  18. pmc Clinical diagnosis and staging of cholangiocarcinoma
    Boris Blechacz
    Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic, 200 First Street, Rochester, MN 55905, USA
    Nat Rev Gastroenterol Hepatol 8:512-22. 2011
    b>Cholangiocarcinoma is the most frequent biliary malignancy. It is difficult to diagnose owing to its anatomic location, growth patterns and lack of definite diagnostic criteria...
  19. ncbi The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma
    Sundeep Singh
    Division of Gastroenterology and Hepatology, Stanford University, 300 Pasteur Dr, Always Building, Room M211, Stanford, CA 94305, USA
    Dig Dis Sci 56:2491-6. 2011
    CA19-9 is a tumor marker for pancreatic cancer, cholangiocarcinoma, and other malignancies. However, its sensitivity and specificity is suboptimal in clinical practice, which we hypothesized limits its clinical utility.
  20. pmc Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping
    Darrell R Borger
    Division of Hematology Oncology, Massachusetts General Hospital, Boston 02114 2698, USA
    Oncologist 17:72-9. 2012
    ..of mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) in tumors from a subset of patients with cholangiocarcinoma. A total of 287 tumors from gastrointestinal cancer patients (biliary tract, colorectal, gastroesophageal, ..
  21. ncbi Rising trends in cholangiocarcinoma: is the ICD classification system misleading us?
    Shahid A Khan
    Liver Unit, Division of Diabetes Endocrinology and Metabolism, Department of Medicine, Imperial College London, London, United Kingdom
    J Hepatol 56:848-54. 2012
    ..We also examined whether coding practices by cancer registries in England and Wales could be influencing these rates...
  22. ncbi Down-regulation of miR-214 contributes to intrahepatic cholangiocarcinoma metastasis by targeting Twist
    Bin Li
    Department of Biliary Truct Surgery I, Eastern Hepatobiliary Hospital, Secondary Military Medicine University, Shanghai, China
    FEBS J 279:2393-8. 2012
    ..However, the mechanisms by which miRNAs regulate intrahepatic cholangiocarcinoma metastasis remain poorly understood...
  23. pmc Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies
    D Sia
    1 HCC Translational Research Laboratory, Liver Unit, Barcelona Clinic Liver Cancer Group, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, Barcelona, Catalonia, Spain 2 Gastrointestinal Surgery and Liver Transplantation Unit, National Cancer Institute, Milan, Italy
    Oncogene 32:4861-70. 2013
    Intrahepatic cholangiocarcinoma (ICC) is an aggressive malignancy with very poor prognosis...
  24. pmc Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study
    Tania M Welzel
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Clin Gastroenterol Hepatol 5:1221-8. 2007
    ..Although the incidence of extrahepatic cholangiocarcinoma (ECC) has remained constant, the incidence of intrahepatic cholangiocarcinoma (ICC) has increased in the ..
  25. pmc Effect of 5-aminolevulinic acid-based photodynamic therapy via reactive oxygen species in human cholangiocarcinoma cells
    Cy Hyun Kim
    National Research and Development Center for Hepatobiliary Cancer, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea
    Int J Nanomedicine 6:1357-63. 2011
    ..We investigated the effect of ALA-based photodynamic therapy (PDT) on human cholangiocarcinoma cells (HuCC-T1)...
  26. ncbi Changing international trends in mortality rates for liver, biliary and pancreatic tumours
    Shahid A Khan
    Liver Unit, Department of Medicine A, Faculty of Medicine, 10th Floor, QEQM Wing, Imperial College School of Medicine, St Mary s Hospital, South Wharf Street, London W2 1PG, UK
    J Hepatol 37:806-13. 2002
    ..However, in England and Wales we previously reported an increase in mortality rates from intrahepatic cholangiocarcinoma. Trends in cholangiocarcinoma in most other industrialized countries are unknown...
  27. pmc Cholangiocarcinoma--controversies and challenges
    Tushar Patel
    Department of Transplantation, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Nat Rev Gastroenterol Hepatol 8:189-200. 2011
    ..The risk factors, clinical presentation, natural history and management of these two types of cholangiocarcinoma are distinct...
  28. ncbi Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma
    Horlad Hasita
    Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
    Cancer Sci 101:1913-9. 2010
    ..phenotypes, and their correlation to angiogenesis, immunosuppression, and clinical prognosis in intrahepatic cholangiocarcinoma (ICC)...
  29. pmc Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment
    Boris Blechacz
    Miles and Shirley Fiterman Center for Digestive Diseases, Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 48:308-21. 2008
  30. ncbi Cholangiocarcinoma and Clonorchis sinensis infection: a case-control study in Korea
    Dongil Choi
    Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50, IlWon Dong, Kangnam Ku, Seoul 135 710, South Korea
    J Hepatol 44:1066-73. 2006
    The authors conducted a hospital-based case-control study to evaluate the role of Clonorchis sinensis infection as a risk factor for the development of cholangiocarcinoma (CC), including extrahepatic CC, in Korea.
  31. ncbi Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States
    T Patel
    Division of Gastroenterology, Scott and White Clinic, Texas A and M University System Health Science Center, College of Medicine, Temple, TX 76508, USA
    Hepatology 33:1353-7. 2001
    ..Thus, our aim was to determine recent trends in the epidemiology of intrahepatic cholangiocarcinoma in the United States...
  32. pmc Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection
    Y Kitagawa
    First Department of Surgery, Nagoya University School of Medicine, Nagoya, Japan
    Ann Surg 233:385-92. 2001
    OBJECTIVE: To assess the status of the regional and paraaortic lymph nodes in hilar cholangiocarcinoma and to clarify the efficacy of systematic extended lymphadenectomy...
  33. ncbi Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines
    Fanyin Meng
    Department of Internal Medicine, Scott and White Clinic, Texas A and M University System Health Science Center College of Medicine, Temple, Texas 76508, USA
    Gastroenterology 130:2113-29. 2006
    ..Our aims were to identify specific miRNA involved in the regulation of cholangiocarcinoma growth and response to chemotherapy.
  34. ncbi Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders
    Jochen Metzger
    Mosaiques diagnostics GmbH, Hannover, Germany
    Gut 62:122-30. 2013
    Diagnosis and curative treatment of cholangiocarcinoma (CC) often comes too late due to the lack of reliable tumour markers especially in patients with primary sclerosing cholangitis (PSC)...
  35. ncbi Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK)1/2
    Hyunho Yoon
    Therapeutic Antibody Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 305 806, Republic of Korea
    Biochem Biophys Res Commun 405:333-7. 2011
    Intrahepatic cholangiocarcinoma (ICC) is an aggressive malignant tumor and is refractory to conventional chemotherapy. The aim of this study is therefore to elucidate the mechanism of chemoresistance in ICC which is not fully understood...
  36. ncbi Thioacetamide-induced intestinal-type cholangiocarcinoma in rat: an animal model recapitulating the multi-stage progression of human cholangiocarcinoma
    Chun Nan Yeh
    Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, Taiwan
    Carcinogenesis 25:631-6. 2004
    b>Cholangiocarcinoma (CCA) is a lethal disease, afflicting many thousands the world over. Human CCA develops through a multi-step progression model, preceded by the onset of dysplasia in the cholangiolar ductal epithelium...
  37. ncbi Epigenetic alterations in cholangiocarcinoma-sustained IL-6/STAT3 signaling in cholangio- carcinoma due to SOCS3 epigenetic silencing
    Hajime Isomoto
    Department of Endoscopy, Nagasaki University Hospital of Medicine and Dentistry, Nagasaki, Japan
    Digestion 79:2-8. 2009
    b>Cholangiocarcinoma (CCA) is a highly lethal malignant tumor arising from the biliary tract epithelium, characterized by its typically late clinical presentation and lack of effective therapeutic modalities...
  38. pmc Crucial role of heme oxygenase-1 on the sensitivity of cholangiocarcinoma cells to chemotherapeutic agents
    Sarinya Kongpetch
    Department of Pharmacology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
    PLoS ONE 7:e34994. 2012
    ..We aimed to investigate roles of HO-1 in human cholangiocarcinoma (CCA) cells for cytoprotection against chemotherapeutic agents...
  39. ncbi Viable metacercariae of Opisthorchis viverrini in northeastern Thai cyprinid fish dishes--as part of a rational program for control of O. viverrini-associated cholangiocarcinoma
    Jiraporn Prasongwatana
    Department of Parasitology, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand
    Parasitol Res 112:1323-7. 2013
    ..This information could be used as part of a rational and sustainable control program for O. viverrini-associated bile duct cancer...
  40. pmc SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma
    Anthony B El-Khoueiry
    University of Southern California Norris Comprehensive Cancer Center, 1441 Eastlake Ave, Suite 3459, Los Angeles, CA 90033, USA
    Invest New Drugs 30:1646-51. 2012
    ..Based on the role of the Ras-Raf-Mek-Erk pathway and the VEGF axis in biliary carcinomas, we conducted a phase II study of sorafenib in patients with advanced biliary cancers...
  41. pmc Dicoumarol enhances gemcitabine-induced cytotoxicity in high NQO1-expressing cholangiocarcinoma cells
    Benjaporn Buranrat
    Department of Pharmacology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand
    World J Gastroenterol 16:2362-70. 2010
    ..whether dicoumarol, a potent inhibitor of NAD(P)H quinone oxidoreductase-1 (NQO1), potentiates gemcitabine to induce cytotoxicity in cholangiocarcinoma cells (CCA) and the role of reactive oxygen generation in sensitizing the cells.
  42. ncbi Usefulness of slimmer and open-cell-design stents for endoscopic bilateral stenting and endoscopic revision in patients with hilar cholangiocarcinoma (with video)
    Jeong Yeol Kim
    Department of Internal Medicine, Pusan National University School of Medicine and Medical Research Institute, Yangsan, Korea
    Gastrointest Endosc 70:1109-15. 2009
    ..metal stenting using a "stent-in-stent" method is currently used to treat patients with unresectable hilar cholangiocarcinoma, this method has limited application in cases of tight strictures or endoscopic revision in case of tumor ..
  43. ncbi Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis
    Tim O Lankisch
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    Hepatology 53:875-84. 2011
    Early detection of malignant biliary tract diseases, especially cholangiocarcinoma (CC) in patients with primary sclerosing cholangitis (PSC), is very difficult and often comes too late to give the patient a therapeutic benefit...
  44. ncbi Overexpression of CD151 as an adverse marker for intrahepatic cholangiocarcinoma patients
    Xiao Yong Huang
    Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, People s Republic of China
    Cancer 116:5440-51. 2010
    ..The objective of the current study was to investigate the expression and role of CD151 and/or c-Met in intrahepatic cholangiocarcinoma (ICC).
  45. ncbi Evaluation of risk factors and clinicopathologic features for intrahepatic cholangiocarcinoma in Southern China: a possible role of hepatitis B virus
    Ning Fu Peng
    Department of Hepatobiliary Surgery, Guangxi Medical University, Guangxi Province, China
    Ann Surg Oncol 18:1258-66. 2011
    Recent efforts suggest an etiologic role of hepatitis B virus (HBV) infection in intrahepatic cholangiocarcinoma (ICC) and the involvement of hepatic progenitor cell in ICC development, without definitive conclusions...
  46. ncbi Optimum palliation of inoperable hilar cholangiocarcinoma: comparative assessment of the efficacy of plastic and self-expanding metal stents
    Ramu P Raju
    Department of Gastroenterology, Hepatology, and Nutrition, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1466, Houston, TX 77030 4009, USA
    Dig Dis Sci 56:1557-64. 2011
    Endoscopic retrograde biliary drainage (ERBD) with plastic or self-expanding metal stents (SEMS) is often performed for palliative care for cholangiocarcinoma.
  47. ncbi Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation
    Zichen Zhang
    Division of Cellular and Molecular Pathogenesis, Department of Pathology, Medical College of Virginia Campus of Virginia Commonwealth University, Richmond, VA, USA
    Hepatology 39:1028-37. 2004
    ..that the cyclooxygenase-2 (COX-2) inhibitor celecoxib acts to significantly suppress the growth of rat C611B cholangiocarcinoma (ChC) cells in vitro...
  48. ncbi Endoscopic bilateral metal stent placement for advanced hilar cholangiocarcinoma: a pilot study of a newly designed Y stent
    Jung Hyun Lee
    Department of Internal Medicine, Pusan National University College of Medicine, Seo Gu, Busan, Korea
    Gastrointest Endosc 66:364-9. 2007
    ..endoscopic stent placement is now generally accepted as a palliative method of treatment in unresectable hilar cholangiocarcinoma, exclusively endoscopic placement of bilateral metal stents has been considered very difficult and complex.
  49. ncbi Expression of stem cell factor and its receptor c-Kit during the development of intrahepatic cholangiocarcinoma
    Tümen Mansuroglu
    Department of Gastroenterology and Endocrinology, Center of Internal Medicine, University of Gottingen, Gottingen, Germany
    Lab Invest 89:562-74. 2009
    ..rat liver, in isolated normal rat liver cells and in a thioacetamide-induced rat model of intrahepatic cholangiocarcinoma (CC)...
  50. pmc The E-cadherin repressor slug and progression of human extrahepatic hilar cholangiocarcinoma
    Ke Jun Zhang
    General Surgery, the Affiliated Hospital of Medical College, Qingdao University, Qing Dao, Shandong Province, 266003, China
    J Exp Clin Cancer Res 29:88. 2010
    This study explored the expression and function of Slug in human extrahepatic hilar cholangiocarcinoma (EHC) to identify its role in tumor progression.
  51. ncbi Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells
    Makiko Taniai
    Mayo Clinic School of Medicine, Rochester, Minnesota 55905, USA
    Cancer Res 64:3517-24. 2004
    ..necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising agent for cancer therapy, including cholangiocarcinoma. However, many cholangiocarcinoma cells are resistant to TRAIL-mediated apoptosis...
  52. ncbi Diagnosis and treatment of cholangiocarcinoma
    Christopher D Anderson
    Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee 37232 4753, USA
    Oncologist 9:43-57. 2004
    b>Cholangiocarcinoma presents a formidable diagnostic and treatment challenge. The majority of patients present with unresectable disease and have a survival of less than 12 months following diagnosis...
  53. pmc Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998
    S D Taylor-Robinson
    Liver Unit, Department of Medicine A, Imperial College School of Medicine, St Mary s Campus, South Wharf Street, London W2 1PG, UK
    Gut 48:816-20. 2001
    ..We further analysed the mortality statistics to determine which anatomical subcategories were involved...
  54. ncbi Liver stem cells and their implication in hepatocellular and cholangiocarcinoma
    T Roskams
    Head Liver Research Unit, Department of Morphology and Molecular Pathology, University of Leuven, Leuven, Belgium
    Oncogene 25:3818-22. 2006
    ..Hepatocellular carcinomas expressing progenitor cell/ductular markers like cytokeratin 19 have a more aggressive clinical course. It is therefore important to recognize this entity...
  55. pmc Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma
    W R Jarnagin
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Surg 234:507-17; discussion 517-9. 2001
    To analyze resectability and survival in patients with hilar cholangiocarcinoma according to a proposed preoperative staging scheme that fully integrates local, tumor-related factors.
  56. ncbi Clonorchiasis: an update
    H J Rim
    Department of Paraitology, College of Medicine, Korea University, Seoul 136 705, Korea
    J Helminthol 79:269-81. 2005
    ..sometimes accompanied by suppurative cholangitis, cholecystitis, cholangiohepatitis and ultimately can cause cholangiocarcinoma. Experimental results on the relationship to the occurrence of cholangiocarcinoma are presented...
  57. pmc miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma
    Nataliya Razumilava
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
    Hepatology 55:465-75. 2012
    ..Although targets and functional roles for a number of microRNAs have been described in cholangiocarcinoma, many additional microRNAs dysregulated in this tumor have not been assigned functional roles...
  58. pmc Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver
    A Tannapfel
    Institute of Pathology, University of Leipzig, Liebigstr 26, 04103 Leipzig, Germany
    Gut 47:721-7. 2000
    ..Inactivation of the tumour suppressor gene p16 (CDKN2/MTS-1/INK4A) and K-ras mutations are among the most frequent genetic alterations in human malignancies...
  59. pmc Cholangiocarcinoma: lessons from Thailand
    Banchob Sripa
    Department of Pathology, Faculty of Medicine, Thailand
    Curr Opin Gastroenterol 24:349-56. 2008
    To present the background of liver fluke-associated cholangiocarcinoma in Thailand focusing on recent epidemiological data and pathogenesis of this bile duct cancer.
  60. ncbi Systemic therapy for biliary tract cancers
    Aram F Hezel
    Tucker Gosnell Center for Gastrointestinal Cancers, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA
    Oncologist 13:415-23. 2008
    ..In this review, we discuss the clinical experience with systemic treatment of BTC, focusing on the rationale for a first-line regimen as well as future directions in the field...
  61. ncbi Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100)
    Banchob Sripa
    Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand
    World J Gastroenterol 11:3392-7. 2005
    To establish and characterize a new cholangiocarcinoma cell line from a patient living in the Opisthorchis viverrini (O. viverrini) endemic area of Northeast Thailand.
  62. ncbi Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin
    Mina Komuta
    Department of Morphology and Molecular Pathology, University Hospitals Leuven, Leuven, Belgium
    Hepatology 47:1544-56. 2008
    ..05), while albumin was downregulated in CLC (P = 0.007) toward K19-negative HCCs. Comparison of CLC with K19-positive HCCs indicated a high homology...
  63. ncbi Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma
    Junji Komori
    Department of Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan
    Hepatology 47:888-96. 2008
    ..studies have demonstrated that patients with primary sclerosing cholangitis have a predisposition to develop cholangiocarcinoma (CC)...
  64. ncbi Expression of LAPTM4B-35: a novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma
    Li Zhou
    Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, Beijing 100032, China
    Cancer Lett 264:209-17. 2008
    ..clinicopathological and prognostic significance of LAPTM4B encoded protein, LAPTM4B-35, in extrahepatic cholangiocarcinoma (EHCC) for specimens from consecutive 81 patients...
  65. pmc Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans
    Hashem B El-Serag
    Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Hepatology 49:116-23. 2009
    ..Previous case control studies indicated a possible association between HCV and intrahepatic cholangiocarcinoma (ICC)...
  66. ncbi Hepatitis B virus infection and risk of intrahepatic cholangiocarcinoma and non-Hodgkin lymphoma: a cohort study of parous women in Taiwan
    Chyng Wen Fwu
    Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA
    Hepatology 53:1217-25. 2011
    ..This study aimed to estimate incidence rates of intrahepatic cholangiocarcinoma (ICC) and non-Hodgkin lymphoma (NHL) and its major subtypes in a nationwide cohort of parous women and to ..
  67. ncbi Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions
    Jesse S Voss
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hum Pathol 44:1216-22. 2013
    b>Cholangiocarcinoma is a highly lethal cancer of the biliary tract. The intrahepatic subtype of cholangiocarcinoma is increasing in incidence globally...
  68. ncbi Radiofrequency ablation for incidentally identified primary intrahepatic cholangiocarcinoma
    Witold Zgodzinski
    Second Department of General Surgery, Skubiszewski Medicaal University of Lublin, Poland
    World J Gastroenterol 11:5239-40. 2005
    b>Cholangiocarcinoma is the second most common primary hepato-biliary malignancy...
  69. pmc Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion
    Apaporn Menakongka
    Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok 10400, Thailand
    World J Gastroenterol 16:713-22. 2010
    To investigate the role of hepatocyte growth factor (HGF) in cholangiocarcinoma (CCA) cell invasiveness and the mechanisms underlying such cellular responses.
  70. ncbi Evaluation of VEGF A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma
    C Möbius
    Department of Surgery II, University of Leipzig, Leipzig, Germany
    Eur J Surg Oncol 33:1025-9. 2007
    ..In extrahepatic cholangiocarcinoma, the VEGF expression and microvessel density have rarely been investigated.
  71. ncbi Magnetic resonance imaging of cholangiocarcinoma
    Riccardo Manfredi
    Department of Radiology, A Gemelli University Hospital, Rome, Italy
    Semin Liver Dis 24:155-64. 2004
    b>Cholangiocarcinoma arises from the bile ducts and is the most common primary malignancy of the biliary tree...
  72. pmc MicroRNA-26a promotes cholangiocarcinoma growth by activating β-catenin
    Jinqiang Zhang
    Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, New Orleans, Louisiana 70112, USA
    Gastroenterology 143:246-56.e8. 2012
    MicroRNAs (miRNAs) have been implicated in the development and progression of human cancers. We investigated the roles and mechanisms of miR-26a in human cholangiocarcinoma.
  73. pmc Establishment and characterisation of six human biliary tract cancer cell lines
    J L Ku
    Laboratory of Cell Biology, Korean Cell Line Bank, Cancer Research Center and Cancer Research Institute, Seoul National University College of Medicine, Seoul 110 744, Korea
    Br J Cancer 87:187-93. 2002
    ..one hilar bile duct cancer), two adenocarcinomas of ampulla of Vater, one intrahepatic bile duct cancer (cholangiocarcinoma), and one adenocarcinoma of the gall bladder...
  74. pmc Worldwide trends in mortality from biliary tract malignancies
    Tushar Patel
    Division of Gastroenterology Scott and White Memorial Hospital and Clinic Texas A and M University System Health Science Center College of Medicine Temple, TX, USA
    BMC Cancer 2:10. 2002
    ..variation in prevalence, some recent studies have suggested an increase in mortality from intrahepatic cholangiocarcinoma in several regions of low endemicity...
  75. ncbi Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells
    Hiroaki Sugiyama
    Department of Gastroenterology, Institute of Clinical Medicine, University of Tsukuba Graduate School of Comprehensive Human Sciences, Tsukuba, Ibaraki, Japan
    J Gastroenterol 46:779-89. 2011
    Intrahepatic cholangiocarcinoma (ICC) is rising in clinical importance due to the increasing incidence worldwide, poor prognosis, and suboptimal response to therapies...
  76. pmc Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes
    Sayaka Sekiya
    Division of Organogenesis and Regeneration, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan
    J Clin Invest 122:3914-8. 2012
    Intrahepatic cholangiocarcinoma (ICC) is the second most common primary malignancy in the liver...
  77. ncbi Altered expression of beta-catenin without genetic mutation in intrahepatic cholangiocarcinoma
    K Sugimachi
    Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    Mod Pathol 14:900-5. 2001
    ..of beta-catenin to determine the role of beta-catenin in cancer formation and/or progression in intrahepatic cholangiocarcinoma (ICC)...
  78. ncbi Anti-tumor activity of all-trans retinoic acid-incorporated glycol chitosan nanoparticles against HuCC-T1 human cholangiocarcinoma cells
    Kyu Don Chung
    Department of Anesthesiology and Pain Medicine, College of Medicine, The Catholic University, Seoul 137 701, Republic of Korea
    Int J Pharm 422:454-61. 2012
    ..RA-incorporated GC nanoparticles were evidently inhibited the proliferation of HuCC-T1 cholangiocarcinoma cells at higher than 20 μg/ml of RA concentration while empty GC vegicles did not affect to the viablity of ..
  79. ncbi L1 cell adhesion molecule is a novel therapeutic target in intrahepatic cholangiocarcinoma
    Jeong Ki Min
    Therapeutic Antibody Research Center, Korea Research Institute of Bioscience and Biotechnology, Chungnam National University School of Medicine, Daejon, Korea
    Clin Cancer Res 16:3571-80. 2010
    Intrahepatic cholangiocarcinoma (ICC), a highly malignant hepatobiliary cancer, has a poor prognosis and is refractory to conventional therapies. The aim of this study is to discover a novel molecular target for the treatment of ICC.
  80. pmc Risk factors for intrahepatic cholangiocarcinoma: a possible role of hepatitis B virus
    M Tanaka
    Department of Cancer Control and Statistics, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
    J Viral Hepat 17:742-8. 2010
    There are several established risk factors for intrahepatic cholangiocarcinoma (ICC), namely primary sclerosing cholangitis, fibropolycystic liver disease, parasitic infection, intrahepatic biliary stones and chemical carcinogen exposure...
  81. ncbi Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors
    Maurizio Cantore
    Department of Oncology, Massa Carrara City Hospital, Massa Carrara, Italy
    Cancer 103:1402-7. 2005
    ....
  82. ncbi Intrahepatic cholangiocarcinoma and hepatocellular carcinoma: differential diagnosis with contrast-enhanced ultrasound
    Li Da Chen
    Department of Medical Ultrasonics, The First Affiliated Hospital, Institute of Diagnostic and Interventional Ultrasound, Sun Yat Sen University, 58 Zhongshan Road 2, Guangzhou 510080, China
    Eur Radiol 20:743-53. 2010
    We assessed the usefulness of contrast-enhanced ultrasound (CEUS) in the differentiation of intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC).
  83. ncbi Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis
    Wei Jing
    Department of General Surgery, Changhai Hospital of Second Military Medical University, Shanghai, China
    Eur J Cancer Prev 21:24-31. 2012
    ..However, its relationship with cholangiocarcinoma (CC), which includes intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC), ..
  84. pmc Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma
    Abdul M Oseini
    Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic and Mayo Clinic Cancer Center, Rochester, MN 55905, USA
    Hepatology 54:940-8. 2011
    ..Many patients with IAC present with biliary strictures and obstructive jaundice, making cholangiocarcinoma (CCA) an important differential diagnosis. We determined the value of sIgG4 in distinguishing IAC from CCA...
  85. ncbi Initial performance profile of a new 6F self-expanding metal stent for palliation of malignant hilar biliary obstruction
    Jennifer Chennat
    Center for Endoscopic Research and Therapeutics, Section of Gastroenterology, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois 60637, USA
    Gastrointest Endosc 72:632-6. 2010
    ..A 6F endoscopic biliary self-expanding metal stent (SEMS) has been newly introduced for intended simultaneous side-by-side bilateral deployment in hilar malignant obstruction...
  86. pmc Cholangiocarcinoma: a compact review of the literature
    Yucel Ustundag
    Department of Internal Medicine, Gastroenterology Clinic, School of Medicine, Hacettepe University, Ankara 06100, Turkey
    World J Gastroenterol 14:6458-66. 2008
    b>Cholangiocarcinoma (CC) is a devastating cancer arising from biliary epithelia. Unfortunately, the incidence of this disease is increasing in Western countries...
  87. ncbi Mimics of cholangiocarcinoma: spectrum of disease
    Christine O Menias
    Department of Radiology, Mallinckrodt Institute of Radiology, St Louis, MO, USA
    Radiographics 28:1115-29. 2008
    b>Cholangiocarcinoma is the second most common primary malignant hepatobiliary neoplasm, accounting for approximately 15% of liver cancers...
  88. ncbi Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3
    Guan Hua Lai
    Division of Cellular and Molecular Pathogenesis, Department of Pathology, Medical College of Virginia Campus of Virginia Commonwealth University, Richmond, Virginia 23298 0297, USA
    Mol Cancer Ther 2:265-71. 2003
    ..inhibitor, effectively blocked tyrosine phosphorylation of p185(neu) overexpressed in cultured rat C611B cholangiocarcinoma (ChC) cells and in neu-transformed WB-F344 rat-liver epithelial stem-like cells (WBneu cells)...
  89. ncbi Liver transplantation for cholangiocarcinoma
    Charles B Rosen
    Division of Transplantation Surgery, Mayo Clinic, Rochester, MN 55905, USA
    Transpl Int 23:692-7. 2010
    ..high dose neoadjuvant radiotherapy with chemosensitization achieves excellent results for patients with early stage, unresectable hilar cholangiocarcinoma or cholangiocarcinoma arising in the setting of primary sclerosing cholangitis.
  90. ncbi Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies
    Edgar Ben-Josef
    Department of Radiation Oncology, Division of Hematology Oncology, University of Michigan, UH B2C490, 1500 E Medical Center Dr, Ann Arbor, MI 48109 0010, USA
    J Clin Oncol 23:8739-47. 2005
    ..A phase II trial was conducted to determine if high-dose radiation with concurrent hepatic arterial floxuridine would improve survival in patients with unresectable intrahepatic malignancies...
  91. ncbi Role of epigenetic alterations in cholangiocarcinoma
    Iris Tischoff
    Institute of Pathology, University of Leipzig, D 04103, Leipzig, Germany
    J Hepatobiliary Pancreat Surg 13:274-9. 2006
    ..At present, little is known about the cellular and molecular mechanisms leading to the development of cholangiocarcinoma. In recent years, in addition to genetic alterations, epigenetic inactivation of (tumor suppressor) genes by ..
  92. ncbi Improved outcome of resection of hilar cholangiocarcinoma (Klatskin tumor)
    Sander Dinant
    Department of Surgery, Academic Medical Center, P O Box 22700, 1100, DE, Amsterdam, The Netherlands
    Ann Surg Oncol 13:872-80. 2006
    Treatment of hilar cholangiocarcinoma (Klatskin tumors) has changed in many aspects...
  93. pmc Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker
    Kusumawadee Utispan
    Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Prannok Road, Bangkok Noi, Bangkok 10700, Thailand
    Mol Cancer 9:13. 2010
    Fibroblasts play important roles in several cancers. It was hypothesized that cholangiocarcinoma (CCA)-associated fibroblasts (Cfs) differ from non-tumorigenic liver fibroblasts (Lfs) in their gene expression profiles resulting in the ..
  94. ncbi Detection of cholangiocarcinoma in vivo using miniprobe-based confocal fluorescence microscopy
    Alexander Meining
    Department of Medicine II, Technical University of Munich, Munich, Germany
    Clin Gastroenterol Hepatol 6:1057-60. 2008
    The preoperative diagnosis of cholangiocarcinoma is associated with a low sensitivity. To overcome this limitation, a new imaging modality was evaluated to detect neoplasia in vivo in the biliary tract.
  95. ncbi Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma
    Jun Sato
    Department of Organ Regenerative Surgery, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960 1295, Japan
    J Hepatobiliary Pancreat Sci 18:700-11. 2011
    Gemcitabine is a promising drug for cholangiocarcinoma treatment. However, the kinetics and metabolism of this drug in cholangiocarcinoma treatment are not well defined...
  96. ncbi Risk factors for cholangiocarcinoma in Khon Kaen, Thailand: a nested case-control study
    Kirati Poomphakwaen
    Dept of Epidemiology, Faculty of Public Health, Mahidol University, Bangkok, Thailand
    Asian Pac J Cancer Prev 10:251-8. 2009
    ..present nested case-control study within the Khon Kaen cohort study was conducted to assess risk factors for cholangiocarcinoma (CCA) development...
  97. ncbi Photodynamic therapy for unresectable cholangiocarcinoma
    Yutaka Tomizawa
    Department of Medicine, University of Pittsburgh Medical Center, 5230 Center Avenue, Pittsburgh, PA 15232, USA
    Dig Dis Sci 57:274-83. 2012
    b>Cholangiocarcinoma (CC) is a rare primary malignancy of the biliary tract with a dismal prognosis. Curative resection can only be applied to a small proportion of early diagnosed patients...
  98. ncbi Effect of surfactant on 5-aminolevulinic acid uptake and PpIX generation in human cholangiocarcinoma cell
    Chung Wook Chung
    Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea
    Eur J Pharm Biopharm 80:453-8. 2012
    Photodynamic therapy (PDT) is a palliative therapy and has been used to cure cholangiocarcinoma (CC), which has a poor prognosis and limited available curative therapy...
  99. pmc Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma
    Hyun Goo Woo
    Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea
    Cancer Res 70:3034-41. 2010
    Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) are the major adult liver cancers...
  100. ncbi Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence
    F Zhang
    Hepatic Surgery Centre, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
    Histopathology 52:224-32. 2008
    Combined hepatocellular cholangiocarcinoma (CHC) is a rare form of primary liver cancer, showing a mixture of hepatocellular and biliary features. Data suggest that most CHC arise from hepatic progenitor cells (HPCs)...
  101. ncbi Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt
    Chang Han
    Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    J Biol Chem 280:24053-63. 2005
    ..This study was designed to examine the mechanisms by which COX-2-derived prostaglandin E2 (PGE2) regulates cholangiocarcinoma cell growth and invasion...

Research Grants57

  1. GROWTH REGULATION OF THE INTRAHEPATIC BILIARY TREE
    GIANFRANCO D ALPINI; Fiscal Year: 2010
    ..liver diseases (cholangiopathies) such as primary biliary cirrhosis, primary sclerosing cholangitis, and cholangiocarcinoma. Cholangiopathies cause morbidity and mortality and are a major public health concern leading to liver ..
  2. Role of liver fluke granulin in cholangiocarcinogenesis
    Jason P Mulvenna; Fiscal Year: 2013
    ..food-borne liver fluke parasites Opisthorchis viverrini and Clonorchis sinensis is a strong risk factor for cholangiocarcinoma (CCA), bile duct cancer, in Thailand, Laos and other locations in East Asia where infection is endemic...
  3. Access to Liver Transplantation for Patients with Primary Sclerosing Cholangitis
    David Seth Goldberg; Fiscal Year: 2011
    ..with PSC face unique complications as compared to other patients with end-stage liver disease, including cholangiocarcinoma (CCA), cholangitis from biliary strictures, and complications such as colon cancer from concomitant ..
  4. Partial-wave spectroscopic microscopy for the diagnosis of cholangiocarcinoma
    Yang Liu; Fiscal Year: 2010
    ..biophotonics technology - partial-wave spectroscopic microscopy (PWS) for the diagnosis and surveillance of cholangiocarcinoma (CCA). CCA is a primary malignancy in bile duct epithelium...
  5. A novel diagnostic biomarker for hepatocellular carcinoma and cholangiocarcinoma
    Xuanyong Lu; Fiscal Year: 2012
    ....
  6. cPLA2alpha and COX-2 in Cholangiocarcinoma
    Tong Wu; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Cholangiocarcinoma is a highly malignant neoplasm of the biliary tract and its incidence and mortality is rising...
  7. Calmodulin Regulates Fas-Mediated Apoptosis: A Target for Cancer Therapy
    Jay M McDonald; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Cholangiocarcinoma is a highly malignant tumor that arises from cholangiocytes of the intra- and extra-hepatic biliary system...
  8. MicroRNA involvement in the regulation of biliary epithelium
    Florin Selaru; Fiscal Year: 2013
    ..The reason for this restriction is that we plan on using the SMAD4/PTEN murine model of cholangiocarcinoma for our in vivo studies. Next, we propose to 2...
  9. A confocal endomicroscope for clinical research
    Michael H Nathanson; Fiscal Year: 2010
    ..secretion and proliferation in disorders characterized by mucosal inflammation, and lymphangiogenesis in cholangiocarcinoma and in other biliary tract diseases...
  10. Mechanisms of Carcinogenesis in Biliary Epithelia
    Gregory J Gores; Fiscal Year: 2013
    ..the cellular mechanisms contributing to the development and progression of biliary tract cancer, termed cholangiocarcinoma (CCA)...
  11. Biomarkers of Opisthorchis viverrini-induced cholangiocarcinoma
    Paul J Brindley; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Cholangiocarcinoma (CCA) - bile duct cancer - is associated with late presentation, poses challenges for diagnosis and has high mortality, features that highlight the need for biomarkers than can be ..
  12. Pathogenesis, Carcinogenesis and Ecology of Opisthorchiasis in Thailand
    Banchob Sripa; Fiscal Year: 2013
    ..Chronic opisthorchiasis often culminates cholangiocarcinoma, cancer of the bile ducts...
  13. Mechanisms of Survival Signaling in Biliary Epithelia
    Tushar Patel; Fiscal Year: 2013
    ..Chronic biliary tract inflammation predisposes to cholangiocarcinoma formation...
  14. PSC Resource Of Genetic Risk, Environment and Synergy Studies (PROGRESS)
    Konstantinos N Lazaridis; Fiscal Year: 2013
    ..to lack of medical therapy, advancement to end-stage liver disease and an increased risk of colon cancer and cholangiocarcinoma (CCA). Thus, while rare in the population, PSC is a notable threat to patients with IBD...
  15. Apoptosis Effectors Targeted By Hedgehog-Supported MicroRNAs
    Justin L Mott; Fiscal Year: 2012
    ..OBJECTIVES of this project are to understand the altered regulation of microRNAs by oncogenic signals in cholangiocarcinoma, and how microRNAs contribute to cell death resistance...
  16. Cholangiocyte microRNAs Regulate Mcl-1 and Cell Death
    Justin L Mott; Fiscal Year: 2011
    ..This proposal outlines a testable hypothesis to define the role of microRNAs as regulators of apoptosis in cholangiocarcinoma, a malignant neoplasm that occurs in the presence of chronic inflammation of bile ducts...
  17. Genetics pathways in intra-hepatic cholangiocarcinoma
    Aram F Hezel; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Intra-hepatic cholangiocarcinoma (IHCC) is a primary cancer of the liver with a rising incidence and poor outcomes that have improved only marginally in recent decades...
  18. ALTERED GROWTH FACTOR PATHWAYS IN BILIARY CANCER
    Alphonse E Sirica; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Intrahepatic cholangiocarcinoma (ICC) is a highly malignant primary neoplasm that is considered to be clinically important and therapeutically challenging due to its increasing incidence, high ..
  19. Pathogenesis of Liver Fluke Induced Cancer in Thailand
    Paul Brindley; Fiscal Year: 2009
    ..There is no stronger link between a human malignancy and a parasitic infection than the link between cholangiocarcinoma (CCA)-hepatic cancer of the bile duct epithelia-and infection with the liver fluke, Opisthorchis viverrini...
  20. Biliary oxysterols and cholangiocarcinoma
    RAHUL P KUVER; Fiscal Year: 2010
    There is a worldwide and steady increase in the incidence of cholangiocarcinoma, a malignancy with very limited treatment options and high mortality...
  21. Protein interactions underlying Fas-mediated DISC in Cholangiocarcinoma
    Yuhua Song; Fiscal Year: 2013
    ..b>Cholangiocarcinoma is a fatal cancer and its rates have been rising worldwide over the past several decades...
  22. Primary Cilia and Malignant Transformation
    Sergio A Gradilone; Fiscal Year: 2013
    ..Our preliminary data shows the absence of cilia in cholangiocarcinoma cells;therefore, ciliary dysfunction may be associated with cancer development...
  23. Aberrant kinase signaling in cholangiocarcinoma
    Tushar Patel; Fiscal Year: 2003
    ..vitro studies on human normal and malignant cholangiocyte cells in culture and an in vivo xenograft model of cholangiocarcinoma. These studies will help us to elucidate the role of p38 MAPK signaling in the growth and spread of ..
  24. Mechanisms of Carcinogenesis in Biliary Epithelia
    Gregory Gores; Fiscal Year: 2006
    ..Chronic inflammation of the biliary tree predisposes to the development of cholangiocarcinoma, a malignant neoplasm originating from cholangiocytes...
  25. DYSREGULATION OF CHOLANGIOCYTE APOPTOSIS BY CYTOKINES
    Tushar Patel; Fiscal Year: 2003
    ..condition affecting the biliary system, is associated with cytokine alterations and the development of cholangiocarcinoma. Dysregulation of apoptosis has recently been implicated as an important contributor to carcinogenesis...
  26. Development of Immunodiagnostics for Pancreatic Cancer
    Hossein Ghanbari; Fiscal Year: 2002
    ..of malignant tumors, including pancreatic carcinoma, glioblastoma multiforme, hepatocellular carcinoma, and cholangiocarcinoma. Additionally, unlike other potential tumor markers, over-expression of HAAH displays high specificity for ..
  27. Hepatic Arterial Flouridine and IV Bevacizumab for Primary Hepatic Malignancy
    William Jarnagin; Fiscal Year: 2008
    ..this protocol targets patients with unresectable hepatocellular carcinoma (HCC) or intrahepatic (peripheral) cholangiocarcinoma (ICC) for continuous infusion of floxuridine (FUDR) combined with systemic bevacizumab...
  28. Pathophysiological Interpretations of Dynamic PET/CT of Molecular Liver Biology
    Susanne Keiding; Fiscal Year: 2010
    ..This will lead to improved diagnosis and treatment of the large groups of patients with liver disease and cancer in the liver. ..
  29. Nonalcoholic steatohepatitis and Cytochrome P450 Enzymes
    Naga P Chalasani; Fiscal Year: 2010
    ..Additionally, we examine the relationship between this enzyme activity and the degree of insulin resistance and lipid peroxidation. ..
  30. BILIARY SECRETORY PATHWAYS IN CYSTIC FIBROSIS
    Won Kyoo Cho; Fiscal Year: 2003
    ..abstract_text> ..
  31. FDG PET-CT in Metastatic Prostate Cancer
    Hossein Jadvar; Fiscal Year: 2010
    ..Rigorous statistical methods will be applied to determine the diagnostic and prognostic performance of FDG PET-CT in this clinical setting. ..
  32. MOLECULAR BASIS OF CELL GROWTH CONTROL BY THE TOR KINASE
    Joseph Avruch; Fiscal Year: 2011
    ..The results of these studies will provide basis for therapeutic interventions in this pathway, which is crucial to both human cancers and to diseases like Type 2 diabetes ..
  33. Surveillance for Hepatocellular Carcinoma among HCV-infected Veterans
    Hashem El Serag; Fiscal Year: 2009
    ..Evaluating the extent and patterns of HCC surveillance is crucial in understanding diffusion (and obstacles) of this practice and in designing interventions to improve the implementation of HCC surveillance. ..
  34. The Role of RR in Chemotherapeutic Drug Resistance
    Yun Yen; Fiscal Year: 2005
    ..Taken together, our proposed studies will provide an integrated evaluation of the molecular control of RR-mediated chemotherapeutic drug resistance. ..
  35. Genetic Basis of Colon Adenoma Synchronous to Carcinoma.
    Yun Yen; Fiscal Year: 2005
    ..We will understand better the biology of different subsets of sporadic CRC, namely CRC+SA, proximal tumors and MSI instable tumors. Our findings will impact on future clinical therapeutic studies of CRC. ..
  36. Evaluation of Biliary Strictures by IDUS, DIA, and FISH
    Michael Levy; Fiscal Year: 2005
    ..Significance: The study results have the potential to significantly improve the accurate diagnosis of biliary strictures. Earlier and more definitive diagnosis will translate into improved treatment options. ..
  37. Wnt Signaling in IBD-Related Colon Cancer
    RANDALL HOLCOMBE; Fiscal Year: 2005
    ..The precise effects of FIPs on Wnt signaling will be defined in vitro, with attention to the potentially disparate responses of different, specific, Fz receptor subtypes. ..
  38. HIV PROTEASE INHIBITORS EFFECT--NENDOTHELIAL DYSFUNCTION
    Changyi Chen; Fiscal Year: 2004
    ..Together, the integrated basic science, non-human primate and human investigations offer a multi disciplinary approach to the understanding and prevention of protease inhibitor-associated vascular complications. ..
  39. Hepatic engraftment of marrow cells in mice and humans
    Neil Theise; Fiscal Year: 2004
    ....
  40. Volume Regulatory Pathways in Cystic Fibrosis Mice
    Won Kyoo Cho; Fiscal Year: 2003
    ..abstract_text> ..
  41. HIV/SIV ENVELOPE GLYCOPROTEIN EFFECTS ON ENDOTHELIA
    Changyi Chen; Fiscal Year: 2002
    ....
  42. Oxidative mutagenesis:Iron, Ascorbic Acid and Genes
    Christopher Bowlus; Fiscal Year: 2002
    ..They will use a mouse model of HH that is prone to hepatocellular formation. ..
  43. BONE MARROW AS A SOURCE FOR PANCREATIC STEM CELLS
    Bryon Petersen; Fiscal Year: 2002
    ..The same data could potentially provide a valuable resource for future tissue engineering and cell therapy technique interventions in pancreatic regeneration. ..
  44. Effects of HIV Protease Inhibitors of Endothelial Barrie
    Changyi Chen; Fiscal Year: 2005
    ..Our findings may also suggest new therapeutic strategies, which may eventually prove effective for the prevention and treatment of these complications. ..
  45. Molecular Surgeon Symposium on Vascular Injury, Repair
    Changyi Chen; Fiscal Year: 2005
    ..A pre-approved letter for acceptance of submission of this application from NIH/NHLBI is included. ..
  46. A Phase 1 Study of CCI-779 in Combination with Imatnib *
    RANDALL HOLCOMBE; Fiscal Year: 2006
    ..Since deregulated kinase activity is known to contribute to a wide range of malignancies, these studies will have applicability to cancer therapy in general. [unreadable] [unreadable]..
  47. Effects of HAART drugs on endothelial dysfunction of pu*
    Changyi Chen; Fiscal Year: 2009
    ..abstract_text> ..
  48. Real-time in Vivo Dosimetry in Radiation Therapy Using Scintillation Detectors
    Sam Beddar; Fiscal Year: 2009
    ..The resulting data can also be used to study dose- related treatment side effects. The ultimate goal of utilizing this method is to improve the delivery of radiotherapy treatments and the quality of life of radiotherapy patients. ..
  49. Listeria Monocytogenes to Treat Hepatic Metastases
    Richard Schulick; Fiscal Year: 2009
    ..Specific Aim 4: Define the role of dendritic cells in the priming and targeting of the immune response. ..
  50. GM-CSF Enhanced Colorectal Cancer Tumor Vaccine Program
    Richard Schulick; Fiscal Year: 2008
    ..abstract_text> ..
  51. Molecular Surgeon Symposium on Genetics and Genomics of Pancreatic Cancer
    Changyi Chen; Fiscal Year: 2008
    ..Furthermore, invited speakers are encouraged to submit manuscripts related to their presentations to "World Journal of Surgery" for consideration of publications. [unreadable] [unreadable] [unreadable]..
  52. Targeting AKT as a novel therapy in pancreatic cancer
    Richard Bold; Fiscal Year: 2007
    ..These results will provide mechanistic as well as pre-clinical data in support of our hypothesis and will allow for the development of novel therapy of human pancreatic cancer. [unreadable] [unreadable] [unreadable]..
  53. Biomarkers of COX-2 inhibitors in intraductal papillary mucinous neoplasm (IPMN)
    Christian Schmidt; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  54. Occult Hepatitis B
    Michael Torbenson; Fiscal Year: 2007
    ..abstract_text> ..
  55. Gene Expression in Barrett's Esophagus
    Hashem El Serag; Fiscal Year: 2006
    ..We present preliminary data on microarray and RT-PCRanalyses on 5 patients with BE that suggest an overactive Wnt pathway: we have also assembled the essential components of a successful study using microarrays. ..
  56. Tissue engineering of small diameter vascular graft
    Changyi Chen; Fiscal Year: 2006
    ..Success of this proposal will directly indicate the clinical applications of tissue engineered small diameter vascular grafts. ..
  57. ANGIOTENSIN II AND REGULATION OF MCP-1 GENE EXPRESSION
    Changyi Chen; Fiscal Year: 2002
    ....